Jonathan Zalevsky, Ph.D.

Jonathan Zalevsky, Ph.D.

Chief Research and Development OfficeratNektar Therapeutics· In proxies 2021–2025

Pay in FY2022-12% from the year before · Nektar Therapeutics stock -83.3% the same year

Jonathan Zalevsky, Ph.D. was paid $4.4M in FY2022 (Dec), down 12%. Nektar Therapeutics stock fell 83.3% that year.

Pay$100 in the stock at the end of FY20 → $13
Pay is from the Summary Compensation Table of each Nektar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Nektar TherapeuticsPublic company · 5 yr
    • Chief Research and Development Officer2021 – Present · 5 yrStock in role -86%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?